Compounds > nsc 251635

Page last updated: 2024-11-06

nsc 251635

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID Source	ID
PubMed CID	72844
SCHEMBL ID	11806721
MeSH ID	M0115117

Synonyms (10)

Synonym
nsc251635
37799-31-8
carbamic acid,4-dihydro-6-[(methoxycarbonyl)amino]-4-oxo-3-phenyl-2-quinazolinyl]phenyl]-, methyl ester
nsc-251635
2-(3'-(methoxycarbonylamino)phenyl)-3-phenyl-6-methoxycarbonylamino-4-(3h)-quinazolone
nsc 251635
carbamic acid, (3-(3,4-dihydro-6-((methoxycarbonyl)amino)-4-oxo-3-phenyl-2-quinazolinyl)phenyl)-, methyl ester
SCHEMBL11806721
methyl hydrogen [3-(6-{[hydroxy(methoxy)methylidene]amino}-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)phenyl]carbonimidate
DTXSID50958840

Research Excerpts

Pharmacokinetics

Excerpt	Reference	Relevance
" Pharmacokinetic data showed that maximal serum phospholipid and NSC 251635 concentrations were obtained at the end of the liposome infusion."	( Intravenous infusion of high doses of liposomes containing NSC 251635, a water-insoluble cytostatic agent. A pilot study with pharmacokinetic data. Atassi, G; Brassinne, C; Coune, A; Frühling, J; Laduron, C; Ruysschaert, JM; Sculier, JP, 1986)	0.75

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	6 (85.71)	18.7374
1990's	1 (14.29)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (14.29%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (85.71%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
nocodazole [no description available]	1.97	1	0	aromatic ketone; benzimidazoles; carbamate ester; thiophenes	antimitotic; antineoplastic agent; microtubule-destabilising agent; tubulin modulator
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	4.45	7	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
pyrazines Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.	1.97	1	0	diazine; pyrazines	Daphnia magna metabolite
nsc 330770 NSC 330770: structure given in first source	1.97	1	0
bis-neodecanoato-1,2-diaminocyclohexaneplatinum(ii) [no description available]	3.08	1	0
nsc 181928 NSC 181928: potently stimulates tubulin-dependent GTP hydrolysis; member of 1-deaza-7,8-dihydropteridine class of mitotic inhibitors with antineoplastic activity; structure given in both sources	1.97	1	0
indium Indium: A metallic element, atomic number 49, atomic weight 114.818, symbol In. It is named from its blue line in the spectrum.. indium atom : A metallic element first identified and named from the brilliant indigo (Latin indicum) blue line in its flame spectrum.	1.96	1	0	boron group element atom
guanosine triphosphate Guanosine Triphosphate: Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety.	1.97	1	0	guanosine 5'-phosphate; purine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite; uncoupling protein inhibitor

Condition	Indicated	Relationship Strength	Studies	Trials
Carcinoma, Oat Cell [description not available]	0	1.96	1	0
Adenocarcinoma, Basal Cell [description not available]	0	1.96	1	0
Di Guglielmo Disease [description not available]	0	1.96	1	0
Cancer of Lung [description not available]	0	2.37	2	0
Benign Neoplasms [description not available]	0	3.58	3	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	0	1.96	1	0
Leukemia, Erythroblastic, Acute A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood.	0	1.96	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	0	2.37	2	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	3.58	3	0
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	0	1.96	1	0
Leukemia L 1210 [description not available]	0	1.96	1	0
Metastase [description not available]	0	1.96	1	0
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	0	1.96	1	0